INVESTMENTS IN VARIABLE INTEREST ENTITIES	6 Months Ended
Jun. 30, 2022
Variable Interest Entities [Abstract]
INVESTMENTS IN VARIABLE INTEREST ENTITIES	INVESTMENTS IN VARIABLE INTEREST ENTITIES Edwards has relationships with various variable interest entities that it does not consolidate as Edwards lacks the power to direct the activities that significantly impact the economic success of these entities. In the second quarter of 2022, the Company entered into an option agreement with a medtech company. Under the option agreement, Edwards paid $60.0 million, of which $10 million was paid in 2021 as a deposit, for an option to acquire the medtech company. The $60.0 million option is included in "Other Assets" on the consolidated condensed balance sheet.In the second quarter of 2022, the Company entered into a convertible promissory note and amended its existing warrant agreement with a medical device company. Under the convertible promissory note agreement, the Company has agreed to loan the medical device company up to $47.5 million, of which $32.5 million has been advanced as of June 30, 2022. In addition, the Company amended its warrant agreement under which the Company had previously paid $35.0 million for an option to acquire the medical device company. The amendment extends the warrant right period. The $35.0 million warrant and the $32.5 million note receivable are included in "Other Assets" on the consolidated condensed balance sheet.

INVESTMENTS IN VARIABLE INTEREST ENTITIES

6 Months Ended

Jun. 30, 2022

Variable Interest Entities [Abstract]

INVESTMENTS IN VARIABLE INTEREST ENTITIES

INVESTMENTS IN VARIABLE INTEREST ENTITIES Edwards has relationships with various variable interest entities that it does not consolidate as Edwards lacks the power to direct the activities that significantly impact the economic success of these entities. In the second quarter of 2022, the Company entered into an option agreement with a medtech company. Under the option agreement, Edwards paid $60.0 million, of which $10 million was paid in 2021 as a deposit, for an option to acquire the medtech company. The $60.0 million option is included in "Other Assets" on the consolidated condensed balance sheet.In the second quarter of 2022, the Company entered into a convertible promissory note and amended its existing warrant agreement with a medical device company. Under the convertible promissory note agreement, the Company has agreed to loan the medical device company up to $47.5 million, of which $32.5 million has been advanced as of June 30, 2022. In addition, the Company amended its warrant agreement under which the Company had previously paid $35.0 million for an option to acquire the medical device company. The amendment extends the warrant right period. The $35.0 million warrant and the $32.5 million note receivable are included in "Other Assets" on the consolidated condensed balance sheet.